Limits...
The Rare Cancer Network: achievements from 1993 to 2012.

Patel A, Ozsahin M, Mirimanoff RO, Bhatia S, Chang K, Miller RC - Rare Tumors (2012)

Bottom Line: Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women.Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients.The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA;

ABSTRACT
The Rare Cancer Network (RCN), founded in 1993, performs research involving rare tumors that are not common enough to be the focus of prospective study. Over 55 studies have either been completed or are in progress.The aim of the paper is to present an overview of the 30 studies done through the RCN to date, organized by disease site. Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women. Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients. Six studies on head and neck cancers include orbital and intraocular lymphoma, mucosal melanoma, pediatric nasopharyngeal carcinoma, olfactory neuroblastoma, and mucosa-associated lymphoid tissue lymphoma of the salivary glands. There were 4 central nervous system studies on patients with cerebellar glioblastoma multiforme, atypical and malignant meningioma, spinal epidural lymphoma and myxopapillary ependymoma. Outside of these disease sites, there is a wide variety of other studies on tumors ranging from uterine leiomyosarcoma to giant cell tumors of the bone. The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports. With further growth of the RCN and collaboration between members our ability to analyze rare tumors will increase and result in better understanding of their behavior and ultimately help direct research that may improve patient outcomes.

No MeSH data available.


Related in: MedlinePlus

Location of Rare Cancer Network Primary Investigators in Europe, Asia (A) and North America (B) for studies published 1993 to 2011.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3475942&req=5

Figure 1: Location of Rare Cancer Network Primary Investigators in Europe, Asia (A) and North America (B) for studies published 1993 to 2011.

Mentions: Currently there are 55 studies either completed or in progress, including data from over 3500 patients, resulting in 28 peer reviewed publications. The median study size was 81 (ranging from 9 to 443). All studies were multi-center retrospective reviews. The studies focused on rare cancers or rare presentations of common cancers. The malignancies covered were of a wide variety with fair distribution among anatomic location and histology. Figure 1 illustrates the geographic location of study primary investigators.


The Rare Cancer Network: achievements from 1993 to 2012.

Patel A, Ozsahin M, Mirimanoff RO, Bhatia S, Chang K, Miller RC - Rare Tumors (2012)

Location of Rare Cancer Network Primary Investigators in Europe, Asia (A) and North America (B) for studies published 1993 to 2011.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3475942&req=5

Figure 1: Location of Rare Cancer Network Primary Investigators in Europe, Asia (A) and North America (B) for studies published 1993 to 2011.
Mentions: Currently there are 55 studies either completed or in progress, including data from over 3500 patients, resulting in 28 peer reviewed publications. The median study size was 81 (ranging from 9 to 443). All studies were multi-center retrospective reviews. The studies focused on rare cancers or rare presentations of common cancers. The malignancies covered were of a wide variety with fair distribution among anatomic location and histology. Figure 1 illustrates the geographic location of study primary investigators.

Bottom Line: Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women.Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients.The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA;

ABSTRACT
The Rare Cancer Network (RCN), founded in 1993, performs research involving rare tumors that are not common enough to be the focus of prospective study. Over 55 studies have either been completed or are in progress.The aim of the paper is to present an overview of the 30 studies done through the RCN to date, organized by disease site. Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women. Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients. Six studies on head and neck cancers include orbital and intraocular lymphoma, mucosal melanoma, pediatric nasopharyngeal carcinoma, olfactory neuroblastoma, and mucosa-associated lymphoid tissue lymphoma of the salivary glands. There were 4 central nervous system studies on patients with cerebellar glioblastoma multiforme, atypical and malignant meningioma, spinal epidural lymphoma and myxopapillary ependymoma. Outside of these disease sites, there is a wide variety of other studies on tumors ranging from uterine leiomyosarcoma to giant cell tumors of the bone. The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports. With further growth of the RCN and collaboration between members our ability to analyze rare tumors will increase and result in better understanding of their behavior and ultimately help direct research that may improve patient outcomes.

No MeSH data available.


Related in: MedlinePlus